BioCryst Pharmaceuticals, Inc.

Historical 13F Holders

Symbol
BCRX
CUSIP
09058V103
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for 09058V103 since 12/18/2024, newest first.

Filer % of Class Filed
RA Capital Management, L.P. 13G/A Amendment 1
6.2% 8/14/2026
Event 6/30/2026
State Street Corp 13G 6.0% 8/7/2026
Event 6/30/2026
State Street Corp 13G 4.9% 5/12/2026
Event 3/31/2026
Vanguard Capital Management LLC 13G 5.2% 4/29/2026
Event 3/31/2026
Vanguard Group Inc 13G/A Amendment 10 0% 3/26/2026
Event 3/13/2026
James E. Flynn 13G/A Amendment 1
6.8% 2/12/2026
Event 12/31/2025
State Street Corp 13G 5.3% 2/9/2026
Event 12/31/2025
RA Capital Management, L.P. 13G
7.3% 11/12/2025
Event 11/4/2025
James E. Flynn 13G
5.8% 9/19/2025
Event 9/12/2025
Avoro Capital Advisors LLC 13G/A Amendment 1
4.2% 5/15/2025
Event 3/31/2025
BlackRock, Inc. 13G/A Amendment 11 8.4% 4/17/2025
Event 3/31/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 5 371 k $3.09 M
2026 Q2 338 266 M $2.89 B
2026 Q1 319 251 M $2.38 B
2025 Q4 293 213 M $1.66 B
2025 Q3 297 195 M $1.48 B
2025 Q2 312 202 M $1.81 B
2025 Q1 289 175 M $1.32 B
2024 Q4 277 168 M $1.26 B
2024 Q3 277 174 M $1.32 B
2024 Q2 259 177 M $1.09 B
2024 Q1 263 186 M $948 M
2023 Q4 255 182 M $1.09 B
2023 Q3 251 176 M $1.24 B
2023 Q2 255 174 M $1.23 B
2023 Q1 261 171 M $1.42 B
2022 Q4 252 169 M $2.21 B
2022 Q3 257 149 M $1.88 B
2022 Q2 239 152 M $1.61 B
2022 Q1 260 128 M $2.10 B
2021 Q4 229 120 M $1.66 B
2021 Q3 221 103 M $1.48 B
2021 Q2 217 105 M $1.65 B
2021 Q1 211 105 M $1.06 B
2020 Q4 198 123 M $914 M
2020 Q3 171 128 M $438 M
2020 Q2 187 133 M $636 M
2020 Q1 148 123 M $245 M
2019 Q4 150 139 M $480 M
2019 Q3 125 98.8 M $283 M
2019 Q2 140 101 M $383 M
2019 Q1 147 102 M $826 M
2018 Q4 135 102 M $827 M
2018 Q3 130 101 M $774 M
2018 Q2 111 88.1 M $505 M
2018 Q1 111 90.0 M $429 M
2017 Q4 124 90.3 M $443 M
2017 Q3 135 83.7 M $439 M
2017 Q2 129 69.1 M $384 M
2017 Q1 135 68.1 M $572 M
2016 Q4 138 58.7 M $372 M
2016 Q3 120 56.6 M $249 M
2016 Q2 105 51.8 M $147 M
2016 Q1 115 55.5 M $157 M
2015 Q4 134 63.1 M $651 M
2015 Q3 138 65.1 M $742 M
2015 Q2 133 63.0 M $941 M
2015 Q1 106 65.1 M $588 M
2014 Q4 100 60.8 M $740 M
2014 Q3 111 56.7 M $555 M
2014 Q2 113 53.4 M $681 M
2014 Q1 93 43.5 M $461 M